Immunovant Inc (IMVT)

02:21 AM

IMVT Shares Drop 2.4% After Batoclimab Fails to Meet Key Goals in Final-Stage Trial - Bitget

02:21 AM

01:06 AM

IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - TradingView

01:06 AM

04:32 AM

Immunovant falls on late-stage trial setback for TED therapy - MSN

04:32 AM

03:16 AM

Immunovant Inc stock: Why biotech investors are watching this closely now - AD HOC NEWS

03:16 AM

Apr 05, 2026

Aberdeen Group plc Increases Stake in Immunovant, Inc. $IMVT - marketbeat.com

Apr 05, 2026

Apr 04, 2026

Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN

Apr 04, 2026

Apr 03, 2026

Immunovant (NASDAQ:IMVT) CEO Sells $342,918.90 in Stock - marketbeat.com

Apr 03, 2026

Apr 03, 2026

Immunovant (IMVT) CEO Venker sells $342,854 in shares By Investing.com - Investing.com India

Apr 03, 2026

Apr 03, 2026

Immunovant (IMVT) CEO Venker sells $342,854 in shares - Investing.com

Apr 03, 2026

Apr 03, 2026

Immunovant (IMVT) CEO settles CVARs into 368,750 shares, disposes stock - stocktitan.net

Apr 03, 2026

Apr 03, 2026

Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm

Apr 03, 2026

Apr 03, 2026

IMVT Should I Buy - Intellectia AI

Apr 03, 2026

Apr 02, 2026

Truist reiterates Hold on Immunovant stock after trial failure By Investing.com - Investing.com India

Apr 02, 2026

Apr 02, 2026

Immunovant's treatment for eye disease fails in late-stage trials - reuters.com

Apr 02, 2026

Apr 02, 2026

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data UpdateSlideshow - Seeking Alpha

Apr 02, 2026

Apr 02, 2026

IMVT: Brepocitinib advances into pivotal LPP trials as batoclimab's TED study informs Graves' strategy - TradingView

Apr 02, 2026

Apr 02, 2026

Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP - Yahoo Finance

Apr 02, 2026

Apr 02, 2026

Leerink cuts Immunovant stock price target on failed TED trial By Investing.com - Investing.com Australia

Apr 02, 2026

Apr 02, 2026

Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM - BioPharma Dive

Apr 02, 2026

Apr 02, 2026

Leerink cuts Immunovant stock price target on failed TED trial - Investing.com

Apr 02, 2026

Apr 02, 2026

Oppenheimer maintains Immunovant stock rating on next-gen drug focus By Investing.com - Investing.com India

Apr 02, 2026

Apr 02, 2026

Oppenheimer maintains Immunovant stock rating on next-gen drug focus - Investing.com UK

Apr 02, 2026

Apr 02, 2026

IMVT: Batoclimab missed its Phase 3 endpoint in thyroid eye disease; focus shifts to IMVT-1402 - TradingView

Apr 02, 2026

Apr 02, 2026

Roivant Shrugs Off Batoclimab Phase III Failure in TED - Citeline News & Insights

Apr 02, 2026

Apr 02, 2026

Immunovant’s batoclimab fails Phase 3 thyroid eye disease trials By Investing.com - Investing.com Canada

Apr 02, 2026

Apr 02, 2026

Hennion & Walsh Asset Management Inc. Makes New Investment in Immunovant, Inc. $IMVT - marketbeat.com

Apr 02, 2026

Apr 02, 2026

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) - manilatimes.net

Apr 02, 2026

Apr 02, 2026

Immunovant’s batoclimab fails Phase 3 thyroid eye disease trials - Investing.com

Apr 02, 2026

Apr 02, 2026

Two late-stage thyroid eye disease trials miss for Immunovant - stocktitan.net

Apr 02, 2026

Apr 01, 2026

Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results - MSN

Apr 01, 2026

Mar 31, 2026

Sjögren’s Syndrome Market Poised for Significant Expansion Through 2034, Driven by Advancing Pipeline Therapies and Rising Disease Burden | DelveInsight Analysis Featuring Astellas Pharma, Immunovant - Barchart.com

Mar 31, 2026

Mar 30, 2026

Responsive Playbooks and the IMVT Inflection - Stock Traders Daily

Mar 30, 2026

Mar 29, 2026

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish - AOL.com

Mar 29, 2026

Mar 28, 2026

EPS Watch: Does PCOR have consistent dividend growthExit Point & Fast Moving Stock Watchlists - baoquankhu1.vn

Mar 28, 2026

Mar 25, 2026

LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN

Mar 25, 2026

Mar 21, 2026

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? - AOL.com

Mar 21, 2026

Mar 21, 2026

Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock - Investing.com India

Mar 21, 2026

Mar 20, 2026

Top Immunovant Executive Quietly Cashes Out in Notable Insider Stock Move - TipRanks

Mar 20, 2026

Mar 20, 2026

Immunovant (NASDAQ:IMVT) Insider Tuyl Christopher Van Sells 2,877 Shares - MarketBeat

Mar 20, 2026

Mar 20, 2026

Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock By Investing.com - za.investing.com

Mar 20, 2026

Mar 20, 2026

Immunovant, Inc. (IMVT) CLO sells 2,877 shares to cover RSU taxes - Stock Titan

Mar 20, 2026

Mar 20, 2026

Bernstein initiates Immunovant stock coverage with neutral rating - Investing.com UK

Mar 20, 2026

Mar 20, 2026

Bernstein initiates Immunovant stock coverage with neutral rating By Investing.com - Investing.com Australia

Mar 20, 2026

Mar 20, 2026

Immunovant (NASDAQ:IMVT) Now Covered by Sanford C. Bernstein - MarketBeat

Mar 20, 2026